Edgewise Therapeutics, Inc (EWTX)

Etorro trading 970x250

About Edgewise Therapeutics, Inc

Address: 3415 Colorado Avenue, Boulder, CO, United States, 80303

Edgewise Therapeutics, Inc News and around…

Latest news about Edgewise Therapeutics, Inc (EWTX) common stock and company :

Chief Scientific Officer Of Edgewise Therapeutics Sold $385K In Stock
11 Oct, 2021 Yahoo! Finance

Russell Alan J, Chief Scientific Officer at Edgewise Therapeutics (NASDAQ:EWTX), made a large insider sell on October 8, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Friday showed that J sold 21,028 shares of Edgewise Therapeutics at prices ranging from $18.03 to $18.56. The total transaction amounted to $386,743. Following the transaction, J still owns 152,294 shares of Edgewise Therapeutics worth $2,523,511. Edgewise Therapeu

Notable Edgewise Therapeutics Insider Makes $105K Sale
06 Oct, 2021 Yahoo! Finance

Russell Alan J, Chief Scientific Officer at Edgewise Therapeutics (NASDAQ:EWTX), made a large insider sell on October 5, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Tuesday showed that J sold 5,778 shares of Edgewise Therapeutics at prices ranging from $18.00 to $18.26. The total transaction amounted to $105,409. Following the transaction, J still owns 173,322 shares of Edgewise Therapeutics worth $3,135,394. Edgewise Therapeu

Edgewise Therapeutics Insider Trades $450K In Company Stock
01 Oct, 2021 Yahoo! Finance

Russell Alan J, Chief Scientific Officer at Edgewise Therapeutics (NASDAQ:EWTX), made a large insider sell on September 29, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that J sold 26,454 shares of Edgewise Therapeutics at prices ranging from $16.83 to $17.47. The total transaction amounted to $452,483. Following the transaction, J still owns 179,100 shares of the company, worth $2,879,032. Edgewise Therapeutic

Chief Scientific Officer Of Edgewise Therapeutics Sold $1.07 Million In Stock
28 Sep, 2021 FinancialContent

Russell Alan J, Chief Scientific Officer at Edgewise Therapeutics (NASDAQ:EWTX), made a large insider sell on September 27, according ...

Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans
25 Sep, 2021 Yahoo! Finance

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Edgewise Therapeutics to Participate at SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1x1 Event on September 23
14 Sep, 2021 FinancialContent

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today that members of its senior management team will participate in the SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1×1 Event, on September 23, 2021. During the event, members of the Company’s leadership team will engage in 1×1 investor meetings. Please contact your SVB Leerink representative to schedule a virtual one-on-one meeting with Edgewise.

The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
27 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
20 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
18 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
17 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Edgewise's Inherited Neuromuscular Disorder Candidate Receives FDA Fast Track Tag
16 Aug, 2021 FinancialContent

TheFDA has granted Fast Track designationtoEdgewise Therapeutics Inc's(NASDAQ: EWTX) EDG-5506 for Becker ...

Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Individuals with Becker Muscular Dystrophy (BMD)
16 Aug, 2021 FinancialContent

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EDG-5506 for the treatment of individuals with BMD. EDG-5506, a selective, small molecule myosin inhibitor designed to protect injury-susceptible fast skeletal muscle fibers in DMD and BMD, is advancing in a Phase 1 clinical trial.

The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
13 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
12 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
11 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Edgewise Therapeutics Reports Second Quarter 2021 Financial Results
09 Aug, 2021 FinancialContent

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, today reported financial results for the second quarter 2021 and recent business highlights.

The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
05 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Edgewise Therapeutics to Present at Wedbush PacGrow Healthcare Conference on August 11
04 Aug, 2021 FinancialContent

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, announced today that members of its management team will participate in a fireside chat and one-on-one investor meetings at the virtual Wedbush PacGrow Healthcare Conference on Wednesday, August 11.

Is Edgewise Therapeutics, Inc. (EWTX) A Good Stock To Buy?
28 Jul, 2021 Yahoo! Finance

After several tireless days we have finished crunching the numbers from nearly 900 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms’ equity portfolios as of March 31st. The results of that effort will be put on display in this article, as […]

12 Health Care Stocks Moving In Wednesday's Intraday Session
21 Jul, 2021 FinancialContent

Gainers Chembio Diagnostics (NASDAQ:CEMI) stock rose 189.72% to $5.97 during Wednesday's regular session. Trading ...

The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
20 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Friday
02 Jul, 2021 FinancialContent

Before 10 a.m. ET on Friday, 43 companies set new 52-week lows. Points of Interest: Autohome (NYSE:ATHM) ...

The Daily Biotech Pulse: Iterum's Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures
02 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Thursday
01 Jul, 2021 FinancialContent

Thursday's morning session saw 13 companies set new 52-week lows. Things to Consider: Edgewise ...

Have Insiders Been Buying Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares This Year?
27 Jun, 2021 Yahoo! Finance

It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...

Edgewise Therapeutics to Present at the PPMD Annual Conference and the New Directions in Biology and Disease of Skeletal Muscle Conference
22 Jun, 2021 FinancialContent

Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, today announced that the company will present at the 2021 PPMD Annual Conference and the 2021 New Directions in Biology and Disease of Skeletal Muscle Conference.

Edgewise Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
01 Jun, 2021 FinancialContent

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, today announced that members of its management team will participate in a fireside chat and one-on-one investor meetings at the virtual Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9, 2021 at 5:30 p.m. ET.

The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
14 May, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

 Edgewise Therapeutics Reports First Quarter 2021 Financial Results and Recent Highlights
13 May, 2021 FinancialContent

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, today reported financial results for the first quarter 2021 and recent business highlights.

Edgewise Therapeutics Reports First Quarter 2021 Financial Results and Recent Highlights
13 May, 2021 Yahoo! Finance

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, today reported financial results for the first quarter 2021 and recent business highlights.

Edgewise Therapeutics, Inc (EWTX) is a NASDAQ Common Stock listed in

970x250